Tenth International Symposium on Regional Cancer Therapies
Sheraton Sand Key Resort
Clearwater Beach, Florida

February 14–16, 2015

Sponsored by
David C. Koch Regional Cancer Therapy Center and University of Pittsburgh School of Medicine Center for Continuing Education in the Health Sciences and UPMC Cancer Centers

In Collaboration with
The University of Maryland Marlene and Stewart Greenebaum Cancer Center The Medical College of Wisconsin Cancer Center

COURSE CO-DIRECTORS
H. Richard Alexander, MD Professor of Surgery University of Maryland School of Medicine Baltimore, Maryland

David L. Bartlett, MD Professor of Surgery University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania

Robert P. Edwards, MD Professor, Obstetrics, Gynecology and Reproductive Sciences University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania

T. Clark Gamblin, MD, MS Associate Professor of Surgery Medical College of Wisconsin Milwaukee, Wisconsin

For additional information or to register online, contact:
https://ccehs.upmc.com

UPMC Cancer Center
Partner with University of Pittsburgh Cancer Institute

David C. Koch Regional Cancer Therapy Center
UPMC Cancer Pavilion, Suite 4135
150 Centre Avenue
Pittsburgh, PA 15232
**Intent and Overview**

This course is designed to cover the most recent advances in cancer therapy that are primarily of a regional focus, such as gastrointestinal, intraperitoneal, hepatic, ovarian and thoracic. Upon completion of the activity, learners from several disciplines should be able to discuss the latest regional therapies in surgical oncology.

**Who Should Attend**

This course is designed for physicians and nurses practicing in the areas of Medical, Surgical, Thoracic, Gynecologic Oncology and Gastroenterology.

**Continuing Education Credit**

The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this live activity for a maximum of 20.25 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Other health care professionals are awarded 2.0 continuing education units (CEU’s) which are equal to 20.2 contact hours.

**Special Needs**

Participation by all individuals is encouraged. Advance notification of any special needs will help us provide better service. Please notify us of your needs at least two weeks in advance of the program by calling Maureen Hewko at (412) 623-5993.

---

**Interactive Audio Response System being used!**

---

**Schedule – Saturday, February 14, 2015**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am</td>
<td>Registration and Breakfast</td>
</tr>
<tr>
<td>6:45 am</td>
<td>Welcome</td>
</tr>
<tr>
<td>7:00 am</td>
<td>Moderators: Steven Ahrendt, MD, and Konstantinos Votanopoulos, MD</td>
</tr>
<tr>
<td>7:15 am</td>
<td>The Role of Ki-67 and Preoperative Clinical Parameters to Select</td>
</tr>
<tr>
<td></td>
<td>Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients to Cytoreduction</td>
</tr>
<tr>
<td></td>
<td>and HIPEC</td>
</tr>
<tr>
<td></td>
<td>Shigeki Kusamura, MD, et. al.</td>
</tr>
<tr>
<td>7:30 am</td>
<td>Clinicopathologic Characteristics and Prognostic Predictors of Survival</td>
</tr>
<tr>
<td></td>
<td>in Patients With Signet Ring or Adenocarcinoma of the Appendix</td>
</tr>
<tr>
<td></td>
<td>Treated with Cytoreductive Surgery and HIPEC</td>
</tr>
<tr>
<td></td>
<td>Chukwuemeka Ihemelandu, MD, et. al.</td>
</tr>
<tr>
<td>7:45 am</td>
<td>Biologic Factors Associated with Survival in Patients with</td>
</tr>
<tr>
<td></td>
<td>Pseudomyxoma Peritonei</td>
</tr>
<tr>
<td></td>
<td>Sean Judge, MD, et. al.</td>
</tr>
<tr>
<td>7:45 am</td>
<td>Diagnostic Laparoscopy is a Safe and Effective Screening Tool for HIPEC</td>
</tr>
<tr>
<td></td>
<td>Rebecca Marmor, MD, et. al.</td>
</tr>
<tr>
<td>8:00 am</td>
<td>Desmoplastic Small Round Cell Tumor: Are all Patients Stage 4?</td>
</tr>
<tr>
<td></td>
<td>Andrea Hayes-Jordan, MD, et. al.</td>
</tr>
<tr>
<td>8:15 am</td>
<td>Outcomes of HIPEC and Cytoreductive Surgery in Young Patients with</td>
</tr>
<tr>
<td></td>
<td>Peritoneal Carcinomatosis</td>
</tr>
<tr>
<td></td>
<td>Mashaal Dhir, MD, et. al.</td>
</tr>
<tr>
<td>8:30 am</td>
<td>A Prognostic Model for Predicting Overall Survival in Patients with</td>
</tr>
<tr>
<td></td>
<td>Peritoneal Carcinomatosis of an Appendiceal Origin Treated with</td>
</tr>
<tr>
<td></td>
<td>Cytoreductive Surgery and HIPEC</td>
</tr>
<tr>
<td></td>
<td>Chukwuemeka Ihemelandu, MD, et. al.</td>
</tr>
<tr>
<td>8:45 am</td>
<td>Knowledge, Attitudes, and Practice of HIPEC Surgeons Regarding Nutrition</td>
</tr>
<tr>
<td></td>
<td>Support</td>
</tr>
<tr>
<td></td>
<td>George Salti, MD, et. al.</td>
</tr>
<tr>
<td>9:00 am</td>
<td>Impact of Major Complications on Patients’ Quality of Life After</td>
</tr>
<tr>
<td></td>
<td>Cytoreductive Surgery and HIPEC</td>
</tr>
<tr>
<td></td>
<td>Trevor Hamilton, MD, et. al.</td>
</tr>
</tbody>
</table>
9:15 am  Cytoreductive Surgery and HIPEC for Patients with Hepatocellular Carcinoma  
Aviram Nissan, MD, et. al.

9:30 am  DEBATE:  
HIPEC is an Accepted Approach for Sarcomatosis  
PRO: Lana Bijelic, MD — CON: Kiran Turaga, MD

10:00 am  Break/Exhibitors/Posters  
Moderators: Robert Edwards, MD, and Marcello Deraco, MD

10:15 am  Risk Stratification and Selection of Patients for Cytoreductive Surgery and HIPEC According to Risk of Procedure Related Mortality  
Shigeki Kusamura, MD, et. al.

10:30 am  Age-Related Morbidity and Mortality with Cytoreductive Surgery and Intraperitoneal Chemotherapy: An ACS NSQIP Database Review  
Madolyn Peters, MD, et. al.

10:45 am  Stoma Creation and Reversal after Cytoreductive Surgery with HIPEC  
Andrea Doud, MD, et. al.

11:00 am  The American Society of Peritoneal Surface Malignancies (ASPSM) Multi-Institution Evaluation of 773 Patients with Epithelial Ovarian Cancer with Peritoneal Metastases  
Jesus Esquivel, MD, et. al.

11:15 am  Systemic Hyperthermia Delivered as Hyperthermic Extracorporeal Applied Tumor Therapy (HEATT), for Recurrent Ovarian Cancer: Case Report of Safe Delivery of Six Cycles  
Roger Vertrees, PhD, et. al.

11:30 am  HIPEC Outcomes in Ovarian Epithelial Cancer at Index Surgery, Salvage and Palliative CRS/HIPEC  
Duncan Watley, MD, et. al.

11:45 am  Cytoreductive Surgery with HIPEC is a Therapeutic Option for Patients with Uterine Leiomyosarcoma after Hysterectomy and Morcellation  
Lana Bijelic, MD, et. al.

Noon  GUEST LECTURER  
Novel Intraperitoneal Immunotherapy Approaches to Ovarian Cancer  
Ronald Alvarez, MD

12:30 pm  Break for Lunch

12:45 pm  CONTROVERSIAL CASE DISCUSSIONS  
Moderator: H. Richard Alexander, MD  
Case Discussants: Edward Levine, MD, Daniel Labow, MD, and John Kane III, MD, Jesus Esquivel, MD, and Brian Loggie, MD

Rapid Recurrence of Low-Grade Mucinous Appendiceal Neoplasm — Chemotherapy or Reoperation or Observation?

Completely Resected Ruptured Mucinous Appendiceal Neoplasm (Low-Grade) — Observation or Reoperation?

High-Volume Colorectal Cancer with Good Response to Chemotherapy, but Persistent High PCI — Is CRS/HIPEC Ever an Option?

Low-Volume, High-Grade Peritoneal Mesothelioma — Chemotherapy or Cytoreductive Surgery Plus HIPEC?

1:30 pm  Saturday Session Adjournment

6:00 pm  Poster Sessions

7:00 pm  MEET THE PROFESSOR RECEPTION  
Presentation of Gabriella Graham Patient Advocate Award

Schedule — Sunday, February 15, 2015

6:30 am  Registration and Breakfast

6:45 am  Welcome  
Moderators: T. Clark Gamblin, MD, MS, and James Pingpank Jr., MD

7:00 am  Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Intrahepatic Cholangiocarcinoma  
Thejus Jayakrishnan, MD, et. al.

7:15 am  Long Term Follow-up of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases  
Roger Olafsson Bagge, MD, et. al.

7:30 am  Safety and Efficacy of Transarterial Chemoembolization in Patients with Transjugular Intrahepatic Portosystemic Shunts  
John Miura, MD, et. al.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:45 am</td>
<td>A Single Institutions Experience with Percutaneous Hepatic Perfusion for Unresectable Melanoma or Sarcoma to the Liver</td>
<td>Omar Rashid, MD, et. al.</td>
</tr>
<tr>
<td>8:00 am</td>
<td>TACE for Metastatic NET with Massive Hepatic Tumor Burden: Is the Benefit Worth The Risk?</td>
<td>Mio Kitano, MD, et. al.</td>
</tr>
<tr>
<td>8:15 am</td>
<td>Treatment of Metastatic Neuroendocrine Tumors (NET) with Transarterial Chemoembolization Using DOX-ELuting Beads (DEBDOX)</td>
<td>Mura Assifi, MD, et. al.</td>
</tr>
<tr>
<td>8:30 am</td>
<td>GUEST LECTURER Update on Liver-Directed Therapies for Hepatic Malignancy</td>
<td>Michael Soulen, MD</td>
</tr>
<tr>
<td>9:00 am</td>
<td>Break/Exhibitors/Posters</td>
<td></td>
</tr>
<tr>
<td>9:00 am</td>
<td>Moderators: Douglas Tyler, MD, and Jonathan Zager, MD</td>
<td></td>
</tr>
<tr>
<td>9:30 am</td>
<td>Overall Survival (OS) Analysis from a Randomized Phase 3 Trial of Talimogene Laherparepvec (T-VEC) versus Subcutaneous Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Patients with Unresectable Regional Melanoma Metastases</td>
<td>Howard Kaufman, MD, et. al.</td>
</tr>
<tr>
<td>9:45 am</td>
<td>Induction of Anti-Melanoma Immunity After Intralesional Ablative Therapy</td>
<td>Amod A. Sarnaik, MD, et. al.</td>
</tr>
<tr>
<td>10:00 am</td>
<td>3D CT for Accurate Isolated Regional Therapy Limb Volume Calculation</td>
<td>Rebecca Tuttle, MD, et. al.</td>
</tr>
<tr>
<td>10:15 am</td>
<td>Lymph Node Ratio is an Important Prognostic Factor in Melanoma</td>
<td>Alessandro Testori, MD, et. al.</td>
</tr>
<tr>
<td>10:30 am</td>
<td>Systemic Anti-Tumor Effects Associated with Ipilimumab Preconditioning and Isolated Limb Perfusion</td>
<td>Minhyung Kim, MD, et. al.</td>
</tr>
<tr>
<td>10:45 am</td>
<td>Melphalan ILI Can Produce an Abscopal Effect in the Presence of Systemic Checkpoint Blockade</td>
<td>Masahito Tsutsui, MD, et. al.</td>
</tr>
<tr>
<td>11:00 am</td>
<td>Exploring Doxorubicin as a Mediator of Immunogenic Cell Death in a Regional Chemotherapy Immune Competent Murine Model of Advanced Extremity Melanoma</td>
<td>Masahito Tsutsui, MD, et. al.</td>
</tr>
<tr>
<td>11:15 am</td>
<td>Break/Exhibitors/Posters</td>
<td></td>
</tr>
<tr>
<td>11:30 am</td>
<td>The Learning Curve of Cytoreductive Surgery and HIPEC: Analysis of 324 Procedures in a Tertiary Center</td>
<td>Wenceslao Vosquez-Jimenez, MD, et. al.</td>
</tr>
<tr>
<td>Noon</td>
<td>Extreme Cytoreductive Surgery and HIPEC: Outcomes from a Single Tertiary Institution</td>
<td>Yaniv Berger, MD, et. al.</td>
</tr>
<tr>
<td>12:15 pm</td>
<td>Mexican National Effort to Integrate Cytoreductive Surgery and HIPEC into the Management of Gastrointestinal and Gynecologic Cancer</td>
<td>Guillermo Flores Ayala, MD, et. al.</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>GUEST LECTURER Theoretical Considerations for an Optimal CRS and HIPEC</td>
<td>Paul Sugarbaker, MD</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>Break for Lunch</td>
<td></td>
</tr>
<tr>
<td>1:15 pm</td>
<td>Best of PSOGI, International Congress on Peritoneal Surface Malignancies</td>
<td>David L. Bartlett, MD</td>
</tr>
<tr>
<td>1:45 pm</td>
<td>Sunday Session Adjournment</td>
<td></td>
</tr>
<tr>
<td>6:00 pm</td>
<td>Poster Viewing</td>
<td></td>
</tr>
<tr>
<td>7:00 pm</td>
<td>ASPSM Meeting</td>
<td></td>
</tr>
</tbody>
</table>
### Schedule – Monday, February 16, 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am</td>
<td>Registration and Breakfast</td>
</tr>
<tr>
<td>6:45 am</td>
<td>Welcome</td>
</tr>
<tr>
<td></td>
<td><strong>Moderators: Haroon Choudry, MD and Joseph Skitzki, MD</strong></td>
</tr>
</tbody>
</table>
| 7:00 am| Clinical Outcome, Genomic Profile Analysis and Possible Therapeutic Options in 11 Patients with Mucinous Appendiceal Neoplasms Treated with Cytoreductive Surgery and HIPEC  
Jesus Esquivel, MD, et. al. |
| 7:15 am| Radiotherapy of Colorectal Peritoneal Carcinomatosis Using a Somatostatin Receptor-Expressing Oncolytic Virus Combined with 177-Lu-DOTATOC  
J. Andrea McCart, MD, et. al. |
| 7:30 am| Proposal for a Renewed Cancer Index (PCI) and Completeness of Cytoreduction (CC) Scores Evaluation Based on Tridimensional Integrated Sharable Digital Tool  
Paolo Sammartino, MD, et. al. |
| 7:45 am| Malignant Peritoneal Mesothelioma: Characterization of Inflammatory Response within the Peritoneal Microenvironment  
Sean Judge, MD, et. al. |
| 8:00 am| HIPEC and IP Treatment in Peritoneal Malignancies  
Glenea Bates, MD, et. al. |
| 8:15 am| Early Identification of DPAM in “At Risk” MAN Patients — A New Approach to MAN Surveillance  
Jason Foster, MD, et. al. |
| 8:30 am| Impact of Restricted Fluid Administration During Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion on Perioperative Outcomes  
James Padussis, MD, et. al. |
| 8:45 am| Conditional Survival as a Patient Centered Metric for Patients with Appendiceal Adenocarcinoma  
Kiran Turaga, MD, et. al. |
| 9:00 am| **GUEST LECTURER**  
A Core Microbiome Associated with the Peritoneal Tumors of PMP  
D. Scott Merrell, PhD |
| 9:30 am| Break/Exhibitors/Posters  
**Moderators: James Cusack, MD, and Garrett Nash, MD** |
| 10:00 am| Promoting Entry into Clinical Trials and Improving Access to Specialist Treatment and Care  
Mary Hessdorfer, NP |
| 10:15 am| Effects of HIPEC on Peritoneal Metastases Developed from Gastric Cancer  
Yutaka Yonemura, MD, et. al. |
| 10:30 am| Matched Case-Control Study of HIPEC for the Prevention and Early Treatment of Colorectal Cancer Peritoneal Metastases  
Dario Baratti, MD, et. al. |
| 10:45 am| Adjuvant HIPEC for Patients with High-Risk Peritoneal-Based Malignancies: Who Benefits and How Much?  
Jeffrey Sussman, MD, et. al. |
| 11:00 am| Conditional Survival After Cytoreductive Surgery with HIPEC for Low and High Grade Appendiceal Primaries  
Harveshp Mogal, MD, et. al. |
| 11:15 am| Malignant Peritoneal Mesothelioma: Incorporation of a Novel Pathologic Grading into a Recently Proposed TNM Classification Improves Outcome Prediction  
Dario Baratti, MD, et. al. |
| 11:30 am| Cytoreductive Surgery and HIPEC in Patients with Liver Involvement  
Yaniv Berger, MD, et. al. |
| 11:45 am| Safety and Efficacy of Concurrent Surgical Therapy for Peritoneal Carcinomatosis and Synchronous Hepatic Metastases in Patients with Disseminated Colorectal Cancer  
Stephanie Downs-Canner, MD, et. al. |
INTERESTING CASE PRESENTATIONS

Moderator: Charles Staley, MD

Cytoreductive Surgery and HIPEC for Fibrolamellar Hepatocellular Carcinoma with Carcinomatosis
Nathan Hinkle, MD, et. al.

Pseudomyxoma Peritonei from a Borderline Mucinous Tumor Arising in an Ovarian Mature Cystic Teratoma
Amareshwar Chiruvella, et. al.

Recurrence of Peritoneal Mesothelioma (originally epitheliod) as a Rapidly Enlarging Mass of Malignant Mesothelioma
Michael D. Kluger, MD

Complete Pathologic Response Found at the Time of CRS and HIPEC for PC from Rectal Cancer
Rajesh Nair, MD

Gastric Cancer Carcinomatosis
Joseph Kim, MD

Desmoplastic Small Round Cell Tumor of the Peritoneal Cavity in a 31-Year-Old Male
James Cusack, MD

Poster Presentations

1. Quality of Life after Isolated Limb Perfusion for In-Transit Metastases of Malignant Melanoma. Roger Olofsson Bagge, MD, et. al.

2. Correlation of Morbidity, PCI and Survival, after HIPEC. Horacio Lopez-Basave, MD, et. al.


5. Peritoneal Metastases Observed in Follow-Up After Robotic Cancer Resections May be Distributed by Gravitational Forces. Paul H. Sugarbaker, MD, et. al.

6. HIPEC for Epithelial Ovarian Cancers: Is There a Role? Michelle Boisen, MD, et. al.


8. Isolated Limb Infusion in a Pregnant Patient with Sarcoma of the Upper Limb: Case Report. Vladimir Milovanov, MD, et. al.


11. Serum Cytokine Levels after Isolated Limb Infusion and Ipilimumab in the Treatment of Malignant Melanoma. Jamie Green, MD, et. al.


13. The ASPSM Multi-Institution Evaluation of Laparoscopic Cytoreductive Surgery and HIPEC. Jesus Esquivel, MD, et. al.


The University of Pittsburgh is an affirmative action, equal opportunity institution.


20. Neoadjuvant Chemotherapy with Bevacizumab Does Not Affect Complications in Patients with Peritoneal Carcinomatosis From Colorectal Cancer Treated by Cytoreduction and HIPEC. Wenceslao Vasquez-Jimenez, MD, et. al.


22. Routine Admission to ICU After Cytoreductive Surgery (CRS) and HIPEC: Not Always a Requirement. Chukwuemeka Obiora, MD, et. al.

23. Outcomes and Histopathologic Correlation According to Age in Patients with Appendiceal Neoplasms After Cytoreductive Surgery with HIPEC. Maria Fernanda Nunez, MD, et. al.


27. Isolated Chemotherapeutic Perfusion as Neoadjuvant Therapy for Advanced/Unresectable Pelvic Malignancy. Harold Wanebo, MD.

**Course Co-Directors**

H. Richard Alexander, MD
Professor of Surgery
University of Maryland School of Medicine
Baltimore, MD

David L. Bartlett, MD
Professor of Surgery
University of Pittsburgh School of Medicine

Robert P. Edwards, MD
Professor, Obstetrics, Gynecology and Reproductive Sciences
University of Pittsburgh School of Medicine

T. Clark Gamblin, MD, MS
Stuart D. Wilson Chair in Surgical Oncology
Chief, Division of Surgical Oncology
Associate Professor of Surgery
Medical College of Wisconsin
Milwaukee, WI

**Invited Faculty**

Steven Ahrendt, MD
Associate Professor of Surgery
University of Pittsburgh School of Medicine

Ronald Alvarez, MD
Professor, Division of Gynecologic Oncology
University of Alabama at Birmingham
Birmingham, AL

Glen Balch, MD
Assistant Professor of Surgery
University of Texas Southwestern Medical Center
Dallas, TX

Lana Bijelic, MD
Medstar Washington Hospital Center
Washington, DC

Haroon Choudry, MD
Assistant Professor of Surgery
University of Pittsburgh School of Medicine

James Cusack, MD
Associate Professor of Surgery
Harvard Medical School
Boston, MA

Marcello Deraco, MD
Surgical Oncologist
Fondazione IRCCS Instituto Nazionale dei Tumori
Milan, Italy

Jesus Esquivel, MD
Medical Director, International Oncology Initiatives
CTCA
Philadelphia, PA

Jason Foster, MD
Associate Professor of Surgery
Nebraska Medical Center
Omaha, NE

Andrea Hayes-Jordan, MD
Assistant Professor of Pediatric Surgery
University of Texas MD Anderson Cancer Center
Houston, TX

Mary Hesdorffer, NP
Executive Director
Mesothelioma Applied Research Foundation
Alexandria, VA

Matthew Holtzman, MD
Associate Professor of Surgery
University of Pittsburgh School of Medicine

John Kane III, MD
Associate Professor of Oncology
Roswell Park Cancer Institute
Associate Professor of Surgery
University of Buffalo
Buffalo, NY

Joseph Kim, MD
Associate Professor of Surgery
City of Hope National Medical Center
Duarte, CA
All individuals in a position to control the content of this education activity are required to disclose all relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.

Faculty reside in the Pittsburgh, Pennsylvania, metropolitan area unless indicated otherwise.

---

Michael Kluger, MD  
Assistant Professor of Surgery  
New York-Presbyterian Hospital  
New York, NY

Daniel Labow, MD  
Associate Professor  
Mt. Sinai School of Medicine  
New York, NY

Edward Levine, MD  
Professor of Surgery  
Wake Forest University  
Winston-Salem, NC

Brian Loggie, MD  
Professor of Surgery  
Creighton University Medical Center  
Omaha, NE

J. Andrea McCart, MD  
Assistant Professor  
University of Toronto  
Toronto, Canada

D. Scott Merrell, PhD  
Professor  
Uniformed Services University  
Bethesda, MD

Rajesh Nair, MD  
Assistant Professor of Surgery  
University of Florida  
Orlando, FL

Garrett Nash, MD  
Assistant Attending Surgeon, MSKCC  
Assistant Professor of Surgery  
Weill-Cornell Medical College  
New York, NY

James Pingpank Jr., MD  
Associate Professor of Surgery  
University of Pittsburgh School of Medicine

Joseph Skitzki, MD  
Assistant Professor  
Roswell Park Cancer Institute and State University of New York  
Buffalo, NY

Michael Soulen, MD  
Professor of Radiology and Surgery  
Director of Interventional Oncology  
Abramson Cancer Center  
University of Pennsylvania  
Philadelphia, PA

Charles Staley, MD  
Professor of Surgery  
Emory University  
Atlanta, GA

Paul H. Sugarbaker, MD  
Director, Program in Peritoneal Surface Malignancy  
Washington Hospital Centre  
Washington, DC

Kiran Turega, MD  
Assistant Professor of Surgery  
Medical College of Wisconsin  
Milwaukee, WI

Douglas S. Tyler, MD  
Professor of Surgery  
Duke University  
Durham, NC

Konstantinos Votanopoulos, MD  
Assistant Professor of Surgery  
Wake Forest University  
Winston-Salem, NC

Jonathan Zager, MD  
Associate Professor of Surgery  
Moffitt Cancer Center  
Tampa, FL

Mura Assifi, MD  
University of Pittsburgh School of Medicine  
Pittsburgh, PA

Guillermo Flores Ayala, MD  
Instituto Jaliscience de Cancerología  
Guadalajara, Mexico

Roger Olofsson Bagge, MD  
Sahlgrenska University Hospital  
Gothenburg, Sweden

Dario Baratti, MD  
Instituto Nazionale Tumori  
Milan, Italy

Horacio Lopez Basave, MD  
Instituto Nacional de Cancerología de Mexico  
Mexico City, Mexico

Glenearea Bates, MD  
Columbia University Medical Center  
New York, NY

Filip Bednar, MD  
University of Pittsburgh School of Medicine  
Pittsburgh, PA

Yaniv Berger, MD  
Mount Sinai Medical Center  
New York, NY

Michelle Boisen, MD  
Magee-Womens Hospital of UPMC  
Pittsburgh, PA

Amareshwar Chiruvella, MD  
Emory Medical Center  
Atlanta, GA

Audrey Choi, MD  
City of Hope National Medical Center  
Duarte, CA

Mashaal Dhir, MD  
University of Pittsburgh School of Medicine  
Pittsburgh, PA

Andrea Doud, MD  
Wake Forest University Department of General Surgery  
Winston-Salem, NC

Stephanie Downs-Canner, MD  
University of Pittsburgh School of Medicine  
Pittsburgh, PA

Vinicius Gava, MD  
Hospital Moinhos de Vento  
Porto Alegre, RS, Brazil

Jamie Green, MD  
Memorial Sloan Kettering Cancer Center  
New York, NY

Vadim Gushchin, MD  
Mercy Medical Center  
Baltimore, MD

Trevor Hamilton, MD  
Mt. Sinai Hospital  
Toronto, Canada

Nathan Hinkle, MD  
University of Tennessee Health Sciences Center  
Memphis, TN

Franco Iafrate, MD  
Sapienza University of Rome  
Rome, Italy

---

~ 14 ~
Registration Information

Online Registration is accepted until **February 13, 2015**. After this date, you are only able to register for the conference on site.

Registering online is the quickest and easiest way to reserve your space at CCEHS conferences.

Visit our online registration site at [https://ccehs.upmc.com](https://ccehs.upmc.com). Scroll down to the *Tenth International Symposium on Regional Cancer Therapies* section on the web page.

- Click the registration button and enter all of the requested information.
- After registering, an electronic confirmation will be sent to the email address you provided when you registered.

Registration is not complete until you receive the confirmation email for your preregistration. If you do not receive this letter within 5-7 days of registration, please contact Maureen Hewko at (412) 623-5993.

**You must bring this confirmation with you to the conference.**

Registration Cancellation

All cancellations must be in writing and sent to us via US mail, email or fax. Tuition cancellations postmarked or date stamped before **January 15, 2015** will be completely refunded. After **January 15, 2015**, a $35 administrative fee will be assessed. No refunds will be made after **February 1, 2015**.

Conference contact for cancellation requests:

Maureen Hewko, MBA
UPMC Cancer Pavilion 413, 5150 Centre Avenue
Pittsburgh, PA 15232
Email: hewkom@upmc.edu • Telephone: (412) 623-5993
Fax: (412) 692-2520

Registration Fees

$300  Physicians and researchers
$200  Nurses and other health care professionals

**Registration fee includes:**
- Continuing education credit
- Registration and course materials
- Continental breakfast, refreshments and a light lunch

Meeting Location

The conference will be held at the Sheraton Sand Key Resort. Conference reservations are at the sole responsibility of the attendees who may contact the hotel. If registering for a room at the hotel online, please go to [http://www.regionaltherapies.com](http://www.regionaltherapies.com) and click on conference information.

If you wish to make your reservation by phone, please call 1-727-595-1611 and refer to code UPMC15.

The cut-off date for reserving a room at the discounted rate of $205 per night is **January 15, 2015**.

Accommodations

**Nightly Guest Room Rate:** $205 per night

*Note: Resorts room rates are subject to additional taxes and resort fees as applicable.*

Transportation

For up-to-date transportation information, go to the Koch Center Website: [http://www.regionaltherapies.com](http://www.regionaltherapies.com)

If you are flying to the conference, the closest airport to the Sheraton is the Tampa International Airport.

For additional information, contact:

Maureen Hewko, MBA
Telephone: (412) 623-5993
Fax: (412) 692-2520
Email: hewkom@upmc.edu
Koch Center Website: [http://www.regionaltherapies.com](http://www.regionaltherapies.com)

Visit the Center for Continuing Education in the Health Sciences Web Site

Our Internet address is: [https://ccehs.upmc.com](https://ccehs.upmc.com)

The UPMC Center for Continuing Education in the Health Sciences invites you to visit our web location. Receive information on CME programs, earn CME credits on the Internet, and access information about our formal courses and much more. Discover who we are and how you can contact us. Please visit our web location often to get updated information on upcoming programs.